Sensorineural Hearing LossAHEADNCT07895004
Comparing an AI-driven Hearing Test With the Standard Hearing Test in Adults With Hearing Loss and Tinnitus
An observational study of Sensorineural Hearing Loss and Tinnitus, run by University College, London at 1 site in United Kingdom.
Trial summary
Background and study aims Hearing problems are becoming more common. In the UK around 18 million adults have hearing loss or hear ringing or buzzing in their ears, which is called tinnitus. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sensorineural Hearing Loss, Tinnitus
- What is being tested?
- Intelligent PTA and Standard pure-tone audiometry (BSA modified Hughson-Westlake)
- How many people
- 84 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 20 Sep 2026to 30 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants are drawn from adults attending outpatient Ear, Nose and Throat (ENT) and Audio-Vestibular Medicine (AVM) clinics at the Royal National ENT and Eastman Dental Hospital, part of University College London Hospitals NHS Foundation Trust in central London. This is a tertiary referral centre, so the clinic population is weighted towards people referred for specialist assessment rather than drawn from the general community. Potential participants are identified by clinical research audiologists, who are members of the same Audiology team that delivers manual pure-tone audiometry to these clinics as part of routine care, by pre-screening upcoming clinic lists on the Epic electronic patient record. Those identified are sent study information approximately two weeks before an outpatient appointment they are already scheduled to attend, and are recruited by invitation at that appointment.
Who may be able to join
- Aged 18 years or over
- Diagnosed with sensorineural hearing loss, or sensorineural hearing loss and concurrent tinnitus
- Sufficient command of English to read, understand and complete questionnaires
- Able to give informed consent
Who cannot join
- Diagnosed with, or reporting, hyperacusis
- Active otologic infection
- History of recent ear surgery
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site
University College London Hospitals
London, Greater London, WC1E 6AA
About this study
Official title: Accuracy, Efficiency and Acceptability of AI-driven Pure-tone Audiometry (AI-PTA) Compared With Manual Pure-tone Audiometry in Adults With Sensorineural Hearing Loss With and Without Concurrent Tinnitus: the AI-enhanced HEaring Assessment and Delivery (AHEAD) Study
Background and study aims
Hearing problems are becoming more common. In the UK around 18 million adults have hearing loss or hear ringing or buzzing in their ears, which is called tinnitus. Many people wait a long time to be seen, partly because there are not enough audiologists - the specialists who test hearing and treat hearing problems.
Read more
The standard hearing test is called pure-tone audiometry. An audiologist plays quiet sounds at different pitches through headphones and the person presses a button each time they hear one. The test is accurate, but it takes 20 to 30 minutes to complete, and needs a trained audiologist for all of that time. For people with tinnitus and comorbidity it can be especially tiring and slow.
The research team has built a version of this test that uses artificial intelligence, called AI-PTA. Instead of following a fixed pattern, it chooses each sound based on the responses already given, which should mean fewer sound presentations are needed to find the same result. The audiologist stays with the person throughout and remains in charge of the test.
This study asks three questions.
- Does AI-PTA give the same hearing results as the standard test?
- Is it quicker?
- And do patients and staff find it acceptable?
Who can participate?
Adults aged 18 or over who have been diagnosed with sensorineural hearing loss, either with or without tinnitus, and who are due to attend the Royal National ENT \& Eastman Dental Hospital in London. Participants need enough English to read and complete questionnaires and to be able to give informed consent. People who have or report hyperacusis (an unusual sensitivity to everyday sounds), an active ear infection, or recent ear surgery cannot take part.
What does the study involve?
People who are interested are sent information about two weeks before a hospital appointment they already have. Those who decide to take part come in about 30 minutes early, meet a research audiologist, discuss the study, and if happy to take part, sign a consent form. They fill in a short questionnaire about their hearing health.
They then have two hearing tests at that visit: the standard test, which is part of their normal care, and the AI-PTA test. Half of the participants have the standard test first and half have AI-PTA first, so that the order does not affect the results.
They come back within a week for a shorter appointment, about 40 minutes, to repeat the AI-PTA test. This shows whether it gives the same response twice. They also fill in a questionnaire about what they think of using artificial intelligence in healthcare. That is the end of taking part, though participants are also invited to join an optional group discussion about their opinions on AI in healthcare later on.
What are the possible benefits and risks of participating?
There is no direct benefit to taking part. The results will help decide whether tests like this can shorten waiting times for hearing assessments in the NHS.
The risks are small. Both tests use the same clinical equipment at the same safe sound levels that ordinary hearing tests use, and a qualified clinical audiologist is present throughout and can stop at any point. The main cost to participants is time: about 45 minutes extra at the first appointment and a second visit of about 40 minutes. Some people find hearing tests tiring, and people with tinnitus sometimes notice their tinnitus more during or after a hearing test. Taking part is voluntary, and choosing not to take part, or stopping at any time, will not affect anyone's care.
Where is the study run from?
Royal National ENT and Eastman Dental Hospitals in London which is part of University College London Hospitals NHS Foundation Trust, and University College London.
When is the study starting and how long is it expected to run for?
The study was approved in August 2026 and the first participant took part in September 2026. It is expected to run for 12 months, finishing in August 2027.
Who is funding the study?
The British Society of Otology (part of ENT UK), and the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre.
Who is the main contact?
Dr Roulla Katiri, uclh.ahead@nhs.net
Read the detailed description
Pure-tone audiometry is the reference standard for measuring hearing thresholds, and the procedure recommended by the British Society of Audiology has been essentially unchanged for decades. It is reliable, but it is also slow: the level of each tone is chosen by a fixed rule rather than by what the previous answers have already established, so a substantial proportion of the presentations in a test carry little information about where the threshold lies. The cost falls on both the patients' and the audiologists' time, which is the binding constraint on access to hearing assessment in the NHS.
AI-PTA addresses this by replacing the fixed rule for choosing the next level. The procedure maintains a probability distribution over the threshold at each ear and frequency, updates it after every response using a psychometric model of hearing, and selects the level of the next tone to maximise the expected information gained about the threshold. Testing at each frequency stops when the standard deviation of that distribution falls below 4 dB and the participant has responded on an ascending run. The starting distribution is drawn from one of four sources, chosen before the test: the participant's own most recently measured audiogram, a clinic population of 75,452 adults seen at this trust, a general population of 19,051 respondents from NHANES (Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data), or a uniform distribution carrying no assumption. Only aggregate tables are used; no individual record from either population is held by the system.
The stopping threshold of 4 dB was fixed before recruitment on the basis of in-silico evaluation across simulated listeners of six audiogram shapes, and is not adjusted during the study. Changing it, or any other parameter capable of moving a measured threshold, would make sessions recorded before and after the change non-comparable, so any such change requires the participants already tested to be treated as a pilot set.
Both procedures are delivered by an audiologist who presents each tone on the department's own calibrated audiometer and records the response in the software. The software instructs and records; it does not generate sound, and it does not decide a threshold that the audiologist cannot override. This is deliberate. The system is a decision support tool operating with a clinician in the loop, not an autonomous test, and every departure from the procedure it proposes is recorded with a reason so that the frequency of such departures can be reported.
Safety constraints are applied identically in both procedures and take precedence over the level selection. Above 80 dB HL the level rises in steps of no more than 5 dB, and no step may cross 80 dB HL without stopping on it, because loudness growth is not linear at high levels and an information calculation that proposes a large step at the top of the range would be correct about the information and wrong about the participant. Maximum output is capped per frequency at the audiometer's calibrated limit, and a clinician may enter lower limits for the equipment actually in the room. The first tone of every session is a familiarisation tone at 40 dB HL whatever the starting distribution suggests, and is excluded from the threshold estimate.
Masking, where the rules indicate it, follows the plateau method of the British Society of Audiology in both procedures. The three indication rules, the 10 dB steps of masking noise and the criterion for a plateau are identical; what differs is only how the threshold is re-established at each level of noise, which is the same difference the study is measuring everywhere else. Bone conduction is likewise handled identically in both.
The design is within-participant and counterbalanced. Each participant receives both procedures, so each acts as their own control and the comparison is not vulnerable to between-participant variation in hearing. The order is randomised to prevent an effect of fatigue, learning or familiarity being attributed to either procedure, and randomisation is stratified by the presence or absence of concurrent tinnitus because tinnitus is expected to affect how reliably a participant responds near threshold, and an imbalance between the groups would otherwise be indistinguishable from a difference between the procedures.
Every presentation is recorded: the level, the response, the state of the estimate at that point, and the time between the instruction appearing and the answer being recorded. Each session also records the version of the procedure that produced it, the version of the software, and the specific build, so that any recorded threshold can be interpreted against the behaviour that produced it. These records support the error analysis, the assessment of agreement between the procedures, and the examination of whether performance differs across age, sex and tinnitus status.
The study is an early-stage clinical evaluation. It is powered to compare the two procedures within participants and is not designed to establish clinical outcomes, cost-effectiveness, or performance in settings or populations other than the one described.
- Conditions
- Sensorineural Hearing Loss, Tinnitus
- Being tested
- Intelligent PTA, Standard pure-tone audiometry (BSA modified Hughson-Westlake)
- Keywords
- Artificial Intelligence, Audiometry, Audiology, Machine Learning, Hearing Loss, Sensorineural Hearing Loss, Tinnitus
- Medical subject headings
- Hearing Loss, Sensorineural, Tinnitus, Hearing Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intelligent PTADiagnostic test
Air-conduction pure-tone audiometry in which the level of each presentation is chosen to maximise expected information about the hearing threshold, from a prior distribution and the responses so far. Testing at a frequency stops when the posterior standard deviation falls below 4 dB with a response on an ascending run. Tones are presented by the audiologist on their own calibrated audiometer; the system instructs and records. Masking follows the BSA plateau method with the same engine establishing the threshold at each masking level.
Standard pure-tone audiometry (BSA modified Hughson-Westlake)Diagnostic test
Air-conduction pure-tone audiometry by the British Society of Audiology's recommended procedure: descending 10 dB steps until no response, ascending 5 dB steps until a response, threshold taken from two responses out of three on ascending runs, with a 1 kHz repeat in the first ear tested. Tones are presented by the audiologist on their own calibrated audiometer.
| Study group | Role | What they receive |
|---|---|---|
| Standard PTA first | Participants randomly allocated to receive Standard PTA before Intelligent PTA at visit 1, and the reverse order at visit 2. Randomisation is stratified by tinnitus status, so this arm contains participants from both clinical groups. Receives: Diagnostic Test: Intelligent PTA; Diagnostic Test: Standard pure-tone audiometry (BSA modified Hughson-Westlake) | |
| AI-PTA first | Participants randomly allocated to receive Intelligent PTA before Standard PTA at visit 1, and the reverse order at visit 2. Randomisation is stratified by tinnitus status, so this arm contains participants from both clinical groups. Receives: Diagnostic Test: Intelligent PTA; Diagnostic Test: Standard pure-tone audiometry (BSA modified Hughson-Westlake) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Agreement between hearing thresholds measured by AI-PTA and by Standard PTA
Mean absolute difference in air-conduction hearing threshold (dB HL) between the two procedures, across all tested frequencies and both ears, measured within the same visit.
Measured: Visit 1 (day 1)
Test-retest reliability of each procedure.
The difference in threshold for the same ear and frequency between visit 1 and visit 2
Measured: Visit 1 to visit 2, up to 7 days
Number of tone presentations, by procedure
Number of tones presented to establish a threshold at every tested frequency, counted separately for each of the two audiometry procedures. Counts are recorded by the system for each test session.
Measured: visit 1 (day 1) and visit 2 (within 7 days of visit 1)
Test duration, by procedure
Time in minutes from the participant's first response to their last.
Measured: Visit 1 (day 1) and visit 2 (within 7 days of visit 1).
Secondary outcomes (1)
Features of AI-assisted healthcare devices that matter to healthcare users, measured by the importance subscale of the Attitudes toward Artificial Intelligence in Healthcare - Adult questionnaire (AAIH-A)
Mean of the 33 importance items of the Attitudes toward Artificial Intelligence in Healthcare - Adult questionnaire, each answered on a five-point scale from 1 (not important) to 5 (extremely important). The subscale score is the mean of the answered items and ranges from 1 to 5. Higher scores indicate greater importance placed on these device features. The subscale describes respondents' priorities and is reported descriptively; it has no better or worse direction.
Measured: Visit 2 (within 7 days of visit 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2026
- Study start20 Sep 2026
- Primary completion23 Aug 2027 (estimated)
- Study completion30 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sensorineural Hearing LossStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 84 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom, University College London Hospitals
- Responsible party
- Sponsor
- Investigators
- Nishchay Mehta, PhD, MBBS, FRCS (ORL-HNS), Principal investigator, University College London Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07895004
- Sponsor's protocol ID
- 206336
- Other IDs
- 354676, 66860, 26/SC/0219
- Acronym
- AHEAD
- Status last verified
- Oct 2026
- First submitted
- 14 Oct 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data underlying the published results, together with the analysis code, will be made available to researchers whose proposed use has been approved by the chief investigators. Requests should be made to the chief investigators. Data will be available from publication for ten years.
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Accuracy, Efficiency and Acceptability of AI-driven Pure-tone Audiometry (AI-PTA) Compared With Manual Pure-tone Audiometry in Adults With Sensorineural Hearing Loss With and Without Concurrent Tinnitus: the AI-enhanced HEaring Assessment and Delivery (AHEAD) Study
- ClinicalTrials.gov ID
- NCT07895004
- Acronym / sponsor ID
- AHEAD / 206336
- Conditions
- Sensorineural Hearing Loss, Tinnitus
- Keywords
- Artificial Intelligence, Audiometry, Audiology, Machine Learning, Hearing Loss, Sensorineural Hearing Loss, Tinnitus
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 84 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom, University College London Hospitals
- Study start
- 20 Sep 2026 (actual)
- Primary completion
- 23 Aug 2027 (estimated)
- Study completion
- 30 Aug 2027 (estimated)
- First posted
- 26 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background and study aims
Hearing problems are becoming more common. In the UK around 18 million adults have hearing loss or hear ringing or buzzing in their ears, which is called tinnitus. Many people wait a long time to be seen, partly because there are not enough audiologists - the specialists who test hearing and treat hearing problems.
The standard hearing test is called pure-tone audiometry. An audiologist plays quiet sounds at different pitches through headphones and the person presses a button each time they hear one. The test is accurate, but it takes 20 to 30 minutes to complete, and needs a trained audiologist for all of that time. For people with tinnitus and comorbidity it can be especially tiring and slow.
The research team has built a version of this test that uses artificial intelligence, called AI-PTA. Instead of following a fixed pattern, it chooses each sound based on the responses already given, which should mean fewer sound presentations are needed to find the same result. The audiologist stays with the person throughout and remains in charge of the test.
This study asks three questions.
- Does AI-PTA give the same hearing results as the standard test?
- Is it quicker?
- And do patients and staff find it acceptable?
Who can participate?
Adults aged 18 or over who have been diagnosed with sensorineural hearing loss, either with or without tinnitus, and who are due to attend the Royal National ENT \& Eastman Dental Hospital in London. Participants need enough English to read and complete questionnaires and to be able to give informed consent. People who have or report hyperacusis (an unusual sensitivity to everyday sounds), an active ear infection, or recent ear surgery cannot take part.
What does the study involve?
People who are interested are sent information about two weeks before a hospital appointment they already have. Those who decide to take part come in about 30 minutes early, meet a research audiologist, discuss the study, and if happy to take part, sign a consent form. They fill in a short questionnaire about their hearing health.
They then have two hearing tests at that visit: the standard test, which is part of their normal care, and the AI-PTA test. Half of the participants have the standard test first and half have AI-PTA first, so that the order does not affect the results.
They come back within a week for a shorter appointment, about 40 minutes, to repeat the AI-PTA test. This shows whether it gives the same response twice. They also fill in a questionnaire about what they think of using artificial intelligence in healthcare. That is the end of taking part, though participants are also invited to join an optional group discussion about their opinions on AI in healthcare later on.
What are the possible benefits and risks of participating?
There is no direct benefit to taking part. The results will help decide whether tests like this can shorten waiting times for hearing assessments in the NHS.
The risks are small. Both tests use the same clinical equipment at the same safe sound levels that ordinary hearing tests use, and a qualified clinical audiologist is present throughout and can stop at any point. The main cost to participants is time: about 45 minutes extra at the first appointment and a second visit of about 40 minutes. Some people find hearing tests tiring, and people with tinnitus sometimes notice their tinnitus more during or after a hearing test. Taking part is voluntary, and choosing not to take part, or stopping at any time, will not affect anyone's care.
Where is the study run from?
Royal National ENT and Eastman Dental Hospitals in London which is part of University College London Hospitals NHS Foundation Trust, and University College London.
When is the study starting and how long is it expected to run for?
The study was approved in August 2026 and the first participant took part in September 2026. It is expected to run for 12 months, finishing in August 2027.
Who is funding the study?
The British Society of Otology (part of ENT UK), and the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre.
Who is the main contact?
Dr Roulla Katiri, uclh.ahead@nhs.net
Detailed description
Pure-tone audiometry is the reference standard for measuring hearing thresholds, and the procedure recommended by the British Society of Audiology has been essentially unchanged for decades. It is reliable, but it is also slow: the level of each tone is chosen by a fixed rule rather than by what the previous answers have already established, so a substantial proportion of the presentations in a test carry little information about where the threshold lies. The cost falls on both the patients' and the audiologists' time, which is the binding constraint on access to hearing assessment in the NHS.
AI-PTA addresses this by replacing the fixed rule for choosing the next level. The procedure maintains a probability distribution over the threshold at each ear and frequency, updates it after every response using a psychometric model of hearing, and selects the level of the next tone to maximise the expected information gained about the threshold. Testing at each frequency stops when the standard deviation of that distribution falls below 4 dB and the participant has responded on an ascending run. The starting distribution is drawn from one of four sources, chosen before the test: the participant's own most recently measured audiogram, a clinic population of 75,452 adults seen at this trust, a general population of 19,051 respondents from NHANES (Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data), or a uniform distribution carrying no assumption. Only aggregate tables are used; no individual record from either population is held by the system.
The stopping threshold of 4 dB was fixed before recruitment on the basis of in-silico evaluation across simulated listeners of six audiogram shapes, and is not adjusted during the study. Changing it, or any other parameter capable of moving a measured threshold, would make sessions recorded before and after the change non-comparable, so any such change requires the participants already tested to be treated as a pilot set.
Both procedures are delivered by an audiologist who presents each tone on the department's own calibrated audiometer and records the response in the software. The software instructs and records; it does not generate sound, and it does not decide a threshold that the audiologist cannot override. This is deliberate. The system is a decision support tool operating with a clinician in the loop, not an autonomous test, and every departure from the procedure it proposes is recorded with a reason so that the frequency of such departures can be reported.
Safety constraints are applied identically in both procedures and take precedence over the level selection. Above 80 dB HL the level rises in steps of no more than 5 dB, and no step may cross 80 dB HL without stopping on it, because loudness growth is not linear at high levels and an information calculation that proposes a large step at the top of the range would be correct about the information and wrong about the participant. Maximum output is capped per frequency at the audiometer's calibrated limit, and a clinician may enter lower limits for the equipment actually in the room. The first tone of every session is a familiarisation tone at 40 dB HL whatever the starting distribution suggests, and is excluded from the threshold estimate.
Masking, where the rules indicate it, follows the plateau method of the British Society of Audiology in both procedures. The three indication rules, the 10 dB steps of masking noise and the criterion for a plateau are identical; what differs is only how the threshold is re-established at each level of noise, which is the same difference the study is measuring everywhere else. Bone conduction is likewise handled identically in both.
The design is within-participant and counterbalanced. Each participant receives both procedures, so each acts as their own control and the comparison is not vulnerable to between-participant variation in hearing. The order is randomised to prevent an effect of fatigue, learning or familiarity being attributed to either procedure, and randomisation is stratified by the presence or absence of concurrent tinnitus because tinnitus is expected to affect how reliably a participant responds near threshold, and an imbalance between the groups would otherwise be indistinguishable from a difference between the procedures.
Every presentation is recorded: the level, the response, the state of the estimate at that point, and the time between the instruction appearing and the answer being recorded. Each session also records the version of the procedure that produced it, the version of the software, and the specific build, so that any recorded threshold can be interpreted against the behaviour that produced it. These records support the error analysis, the assessment of agreement between the procedures, and the examination of whether performance differs across age, sex and tinnitus status.
The study is an early-stage clinical evaluation. It is powered to compare the two procedures within participants and is not designed to establish clinical outcomes, cost-effectiveness, or performance in settings or populations other than the one described.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard PTA first | – | Diagnostic Test: Intelligent PTA, Diagnostic Test: Standard pure-tone audiometry (BSA modified Hughson-Westlake)Participants randomly allocated to receive Standard PTA before Intelligent PTA at visit 1, and the reverse order at visit 2. Randomisation is stratified by tinnitus status, so this arm contains participants from both clinical groups. |
| AI-PTA first | – | Diagnostic Test: Intelligent PTA, Diagnostic Test: Standard pure-tone audiometry (BSA modified Hughson-Westlake)Participants randomly allocated to receive Intelligent PTA before Standard PTA at visit 1, and the reverse order at visit 2. Randomisation is stratified by tinnitus status, so this arm contains participants from both clinical groups. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants are drawn from adults attending outpatient Ear, Nose and Throat (ENT) and Audio-Vestibular Medicine (AVM) clinics at the Royal National ENT and Eastman Dental Hospital, part of University College London Hospitals NHS Foundation Trust in central London. This is a tertiary referral centre, so the clinic population is weighted towards people referred for specialist assessment rather than drawn from the general community. Potential participants are identified by clinical research audiologists, who are members of the same Audiology team that delivers manual pure-tone audiometry to these clinics as part of routine care, by pre-screening upcoming clinic lists on the Epic electronic patient record. Those identified are sent study information approximately two weeks before an outpatient appointment they are already scheduled to attend, and are recruited by invitation at that appointment.
Key inclusion criteria (4 listed)
- Aged 18 years or over
- Diagnosed with sensorineural hearing loss, or sensorineural hearing loss and concurrent tinnitus
- Sufficient command of English to read, understand and complete questionnaires
- Able to give informed consent
Key exclusion criteria (3 listed)
- Diagnosed with, or reporting, hyperacusis
- Active otologic infection
- History of recent ear surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intelligent PTAAir-conduction pure-tone audiometry in which the level of each presentation is chosen to maximise expected information about the hearing threshold, from a prior distribution and the responses so far. Testing at a frequency stops when the posterior standard deviation falls below 4 dB with a response on an ascending run. Tones are presented by the audiologist on their own calibrated audiometer; the system instructs and records. Masking follows the BSA plateau method with the same engine establishing the threshold at each masking level. | Diagnostic test | AI-PTA first, Standard PTA first |
| Standard pure-tone audiometry (BSA modified Hughson-Westlake)Air-conduction pure-tone audiometry by the British Society of Audiology's recommended procedure: descending 10 dB steps until no response, ascending 5 dB steps until a response, threshold taken from two responses out of three on ascending runs, with a 1 kHz repeat in the first ear tested. Tones are presented by the audiologist on their own calibrated audiometer. | Diagnostic test | AI-PTA first, Standard PTA first |
Primary outcome
Agreement between hearing thresholds measured by AI-PTA and by Standard PTA
Time frame: Visit 1 (day 1)
Mean absolute difference in air-conduction hearing threshold (dB HL) between the two procedures, across all tested frequencies and both ears, measured within the same visit.
Test-retest reliability of each procedure.
Time frame: Visit 1 to visit 2, up to 7 days
The difference in threshold for the same ear and frequency between visit 1 and visit 2
Number of tone presentations, by procedure
Time frame: visit 1 (day 1) and visit 2 (within 7 days of visit 1)
Number of tones presented to establish a threshold at every tested frequency, counted separately for each of the two audiometry procedures. Counts are recorded by the system for each test session.
Test duration, by procedure
Time frame: Visit 1 (day 1) and visit 2 (within 7 days of visit 1).
Time in minutes from the participant's first response to their last.
1 secondary outcome
Features of AI-assisted healthcare devices that matter to healthcare users, measured by the importance subscale of the Attitudes toward Artificial Intelligence in Healthcare - Adult questionnaire (AAIH-A)
Time frame: Visit 2 (within 7 days of visit 1)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Protocols.io In-Situ Validation Protocol: Bayesian Pure-Tone AudiometryLink provided by the sponsor.
- BSA - Pure-tone air-conduction and bone- conduction threshold audiometry with and without maskingLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified individual participant data underlying the published results, together with the analysis code, will be made available to researchers whose proposed use has been approved by the chief investigators. Requests should be made to the chief investigators. Data will be available from publication for ten years.
Related trials for Sensorineural Hearing Loss
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruiting
Effect of a Totally Implantable Cochlear Implant on Tinnitus Severity in Adults With Preoperative Tinnitus
Sensorineural Hearing Loss, Tinnitus
Active, not recruiting
An Investigation to Evaluate Sound Coding Enhancements in Adult Cochlear Implant Recipients
Cochlear Implant Recipients, Hearing Loss, Cochlear
RecruitingPhase 2
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
Sudden Hearing Loss
Active, not recruiting
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
Hearing Loss, Sensorineural, Hearing Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nishchay Mehta, PhD, MBBS, FRCS (ORL-HNS) principal investigator
University College London Hospitals
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sensorineural Hearing Loss and Tinnitus, run by University College, London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Agreement between hearing thresholds measured by AI-PTA and by Standard PTA (time frame: Visit 1 (day 1)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.